Representation of Triton:

• on its sale of Ramudden Global, a leading international provider of traffic management and infrastructure safety supporting the maintenance and upgrade of essential transport and utility networks, to I Squared Capital.
• on its £1.3 billion recommended takeover offer for Clinigen Group plc, through funds managed by leading private equity firm Triton.
• on the acquisition of O'Connor Trading Holdings Limited, the holding company of a leading UK multi-utility services specialist business operating within regulated infrastructure, from its founders Tim and Tom O'Connor.

Representation of Bridgepoint Advisers II Limited on its acquisition of NMi Group, a group of businesses that specialise in testing, inspection, certification and calibration.

Representation of EQT and IFS on the minority stake sale and investment in enterprise software provider IFS, a leading provider of cloud enterprise software and Industrial AI applications.

Representation of Ramudden Global, a portfolio company of Triton Fund IV, on its acquisition of Curtin Co., LLC and Carolina Traffic Devices, LLC, a leading North American provider of traffic management solutions.

Representation of Macquarie Asset Management (MAM) on the acquisition by a consortium led by MAM of a 60% stake in National Grid plc’s UK gas transmission and metering business.

Representation of CVC Growth on its acquisition of Brightstarr Group (Unily), a market leading Ex SaaS platform enhancing employee engagement for global enterprises with subsidiaries in the US and Australia.

Representation of Morgan Stanley Infrastructure Partners, global leader in private infrastructure equity investing, on its sale of its 50% interest in in Höegh Evi, a global provider of liquified natural gas and floating energy infrastructure, to Igneo Infrastructure Partners.

Representation of Oaktree Capital Management and Cornerstone Investment Management on their sale of Avenga, a software engineering and consulting services provider, to KKCG, a Czech private investment group.

Representation of Oaktree Capital Management (UK) LLP in its acquisition of the OEG Group (one of the leading offshore cargo carrying equipment suppliers in the world) via the Oaktree Power Opportunities Fund.

Representation of Clinigen Limited, a global pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supplies, on its sale of Proleukin® to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ('Iovance'), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumour infiltrating lymphocyte (TIL) and peripheral-blood lymphocyte (PBL)).